# GLOW Stack

> GLOW Stack combines BPC-157, TB-500, and GHK-Cu to target soft-tissue recovery, mobility, collagen remodeling, and skin-matrix support.

Canonical: https://pepflow.app/stacks/glow-stack/

Recovery-and-skin stack combining BPC-157, TB-500, and GHK-Cu for repair, mobility, and skin-matrix support discussions.

Recovery Inflammation Gut repair Muscle repair Skin Hair Anti-aging

[BPC-157](<https://pepflow.app/peptides/bpc-157/>) [TB-500](<https://pepflow.app/peptides/tb-500/>) [GHK-Cu](<https://pepflow.app/peptides/ghk-cu/>)

## Overview

GLOW is a three-component recovery and skin-matrix stack built around BPC-157, TB-500, and GHK-Cu. It is used to frame soft-tissue repair, cell migration, collagen and extracellular-matrix remodeling, and post-procedure skin-support discussions.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/34267654/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/22074294/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/26236730/>)

The roles are complementary: BPC-157 covers localized repair, TB-500 covers migration and remodeling, and GHK-Cu covers copper-peptide skin and matrix biology. The exact three-peptide combination still lacks controlled human outcome evidence.[\[7\]](<https://pubmed.ncbi.nlm.nih.gov/16847171/>) [\[9\]](<https://clinicaltrials.gov/study/NCT07437586>) [\[10\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

## Peptides in this stack

- [BPC-157](<https://pepflow.app/peptides/bpc-157/>) - Endogenous fragment peptide · A gastric pentadecapeptide studied for gut, wound, vascular, and soft-tissue repair biology, with strong animal data but limited human outcomes. · Recovery Inflammation Gut repair +1 · C Preliminary Limited Data

- [TB-500](<https://pepflow.app/peptides/tb-500/>) - Endogenous fragment peptide · A thymosin beta-4 fragment discussed for wound, ocular, cardiac, and soft-tissue repair, with limited direct TB-500 human evidence. · Soft-tissue recovery Inflammation support Muscle repair · C Emerging Limited Data

- [GHK-Cu](<https://pepflow.app/peptides/ghk-cu/>) - Matrikine/copper tripeptide · A well-characterized copper-binding tripeptide best known for topical skin remodeling, with relevant human data and weaker support for injectable or systemic use. · Skin Hair Recovery +2 · B Moderate Moderate Data

## Why They're Combined

BPC-157 and TB-500 cover the recovery base: local repair signaling, tissue-protection rationale, cell migration, and wound-healing biology. GHK-Cu adds the skin and matrix layer through copper-peptide effects on collagen, glycosaminoglycans, fibroblast activity, and skin-regeneration pathways.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/34267654/>) [\[5\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2701135/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/26236730/>)

That makes GLOW most coherent when the goal includes soft-tissue recovery plus visible tissue quality, such as skin appearance or post-procedure support. The combination should still be judged as a stack, not as three separate benefit claims automatically added together.[\[7\]](<https://pubmed.ncbi.nlm.nih.gov/16847171/>) [\[10\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>) For scheduling terminology, read the [peptide stack planning guide](<https://pepflow.app/blog/how-to-stack-peptides/>).

## How They Work Together

The proposed mechanism is repair signal plus migration plus matrix remodeling. BPC-157 is discussed for tendon-cell survival, migration, and angiogenesis signals. Thymosin beta-4 biology is tied to actin handling and epithelial repair, while GHK-Cu is tied to fibroblast and extracellular-matrix activity.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/21030672/>) [\[5\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2701135/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/3169264/>)

The practical idea is broader recovery coverage: one component for local tissue signals, one for movement of repair cells, and one for collagen and skin-matrix support. The weak point is delivery, because topical, injectable, and mixed-product contexts are not interchangeable and should not be interpreted as the same evidence base.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/26236730/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/16847171/>) [\[9\]](<https://clinicaltrials.gov/study/NCT07437586>)

## What the Evidence Shows

GLOW has component support, not stack-level evidence. BPC-157 and TB-500 lean heavily on preclinical and review-level recovery evidence. GHK-Cu has topical human skin context and active wound-healing trial activity, but that evidence is route-specific.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40756949/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/22074294/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/16847171/>) [\[9\]](<https://clinicaltrials.gov/study/NCT07437586>)

No controlled human study establishes that the three-peptide stack improves injury recovery, skin appearance, or post-procedure outcomes beyond simpler approaches. The stack is best treated as a mechanistic and practical hypothesis with route-specific boundaries and modest confidence.[\[10\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>) [\[11\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

## Typical Protocol

Common GLOW schedules keep BPC-157 at 250-500 mcg once or twice daily and TB-500 at 2-4 mg per dose, 2-3 times weekly. GHK-Cu stays route-specific: topical cosmetic products often sit around 1-3% once or twice daily, while injectable-style protocols commonly use 1-2 mg per dose.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/34267654/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/22074294/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/26236730/>)

The cleaner stack plan separates the recovery block from the skin routine: fixed BPC-157 and TB-500 injection days, a consistent topical GHK-Cu routine if used topically, and a 4-8 week first review window for recovery or post-procedure tracking.[\[7\]](<https://pubmed.ncbi.nlm.nih.gov/16847171/>) [\[10\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

[Full GLOW Stack dosage guide →](<https://pepflow.app/stacks/glow-stack/dosage/>)

## Important Considerations

Keep topical and injectable GHK-Cu separate when reading this stack. Topical GHK-Cu skin data can support a cosmetic or wound-context rationale, but it should not be used as proof for injectable GHK-Cu or for a three-peptide recovery stack. The GLOW combination is still component-led, not validated as a stack.[\[7\]](<https://pubmed.ncbi.nlm.nih.gov/16847171/>) [\[9\]](<https://clinicaltrials.gov/study/NCT07437586>) [\[11\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

If GLOW is encountered as a fixed-ratio or pre-mixed blend, independent titration becomes harder and stability, storage, and potency questions matter more. Irritation, injection-site issues, recovery changes, or no clear signal can overlap, so start-point logs, stable training load, route-specific tracking, and athlete anti-doping review matter.[\[10\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>) [\[11\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[12\]](<https://ita.sport/resource/wada-2026-prohibited-list/>) For preparation terminology, read the [mixing versus co-scheduling explainer](<https://pepflow.app/blog/can-you-mix-peptides-together/>).

## Published research 12 sources

- [Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.](<https://pubmed.ncbi.nlm.nih.gov/34267654/>) - \[1\] · PubMed / Frontiers in Pharmacology, 2021. review.

- [Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.](<https://pubmed.ncbi.nlm.nih.gov/40756949/>) - \[2\] · PubMed / HSS Journal, 2025. review.

- [The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.](<https://pubmed.ncbi.nlm.nih.gov/21030672/>) - \[3\] · PubMed / Journal of Applied Physiology, 2011. in vitro.

- [Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications.](<https://pubmed.ncbi.nlm.nih.gov/22074294/>) - \[4\] · PubMed / Expert Opinion on Biological Therapy, 2012-01. review.

- [Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent.](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2701135/>) - \[5\] · PMC / Clinical Ophthalmology, 2007. review.

- [GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.](<https://pubmed.ncbi.nlm.nih.gov/26236730/>) - \[6\] · PubMed / BioMed Research International, 2015. review.

- [Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin.](<https://pubmed.ncbi.nlm.nih.gov/16847171/>) - \[7\] · PubMed / Archives of Facial Plastic Surgery, 2006. human clinical.

- [Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+.](<https://pubmed.ncbi.nlm.nih.gov/3169264/>) - \[8\] · PubMed / FEBS Letters, 1988. in vitro.

- [Topical GHK-Cu Gel for Acute Skin Wound Healing](<https://clinicaltrials.gov/study/NCT07437586>) - \[9\] · ClinicalTrials.gov, 2026. clinical trial registry.

- [Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.](<https://pubmed.ncbi.nlm.nih.gov/41966639/>) - \[10\] · PubMed / Sports Medicine, 2026. review.

- [Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) - \[11\] · U.S. Food and Drug Administration, 2026-04-22. regulatory.

- [The 2026 List of Prohibited Substances and Methods](<https://ita.sport/resource/wada-2026-prohibited-list/>) - \[12\] · World Anti-Doping Agency, 2026. regulatory.

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/#guide-coverage>)

## Quick facts

**Components**

[BPC-157](<https://pepflow.app/peptides/bpc-157/>) Preliminary [TB-500](<https://pepflow.app/peptides/tb-500/>) Emerging [GHK-Cu](<https://pepflow.app/peptides/ghk-cu/>) Moderate

**Citations**

[12 sources](<https://pepflow.app/stacks/glow-stack/#published-research>)

**Updated**

Aug 17, 2026

### Potential benefits

- Recovery
- Inflammation
- Gut repair
- Muscle repair
- Skin
- Hair

## Related

- [BPC-157 Peptide](<https://pepflow.app/peptides/bpc-157/>)
- [TB-500 Peptide](<https://pepflow.app/peptides/tb-500/>)
- [GHK-Cu Peptide](<https://pepflow.app/peptides/ghk-cu/>)
- [How to Stack Peptides: A Practical Protocol Guide](<https://pepflow.app/blog/how-to-stack-peptides/>)
